IRMD
VENTE TOTALE: 1 419 titres (~122 658,36 $ US)
- Insiders
- ALLEN MONTY K
- Total bought
- —
- Total sold
- $122,658
- Last activity
- 2026-09-03
- Last synced
-
2026-09-09 09:58:02
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-08
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 76.7% | 76.9% | 76.5% | 77.4% | 76.6% | |
| Ebit Margin | 33.8% | 33.1% | 33.2% | 30.4% | 23.5% | |
| Ebitda Margin | 36.7% | 34.3% | 34.3% | 31.6% | 26.9% | |
| Operating Profit Margin | 31.2% | 30.0% | 30.6% | 29.3% | 23.5% | |
| Pretax Profit Margin | 33.8% | 33.1% | 33.2% | 30.4% | 23.5% | |
| Continuous Operations Profit Margin | 26.8% | 26.3% | 26.2% | 24.1% | 22.3% | |
| Net Profit Margin | 26.8% | 26.3% | 26.2% | 24.1% | 22.3% | |
| Bottom Line Profit Margin | 26.8% | 26.3% | 26.2% | 24.1% | 22.3% | |
| Current Ratio | 7.977 | 8.839 | 4.655 | 9.059 | 11.175 | |
| Quick Ratio | 6.835 | 7.617 | 3.870 | 8.431 | 10.545 | |
| Solvency Ratio | 1.756 | 1.743 | 0.866 | 1.140 | 1.002 | |
| Cash Ratio | 5.025 | 6.136 | 3.048 | 6.776 | 9.087 | |
| Price To Earnings Ratio | 54.960 | 36.184 | 34.904 | 27.735 | 60.803 | |
| Price To Earnings Growth Ratio | 3.342 | 3.076 | 1.047 | 0.811 | 0.103 | |
| Forward Price To Earnings Growth Ratio | 3.342 | 3.076 | 1.047 | 0.811 | 0.103 | |
| Price To Earnings Diluted Ratio | 55.589 | 36.667 | 35.163 | 27.735 | 62.446 | |
| Price To Earnings Diluted Growth Ratio | 3.335 | 3.300 | 1.087 | 0.733 | 0.109 | |
| Price To Book Ratio | 13.080 | 8.027 | 8.377 | 4.824 | 7.905 | |
| Price To Sales Ratio | 14.766 | 9.514 | 9.125 | 6.668 | 13.644 | |
| Price To Free Cash Flow Ratio | 72.029 | 39.551 | 109.615 | 43.513 | 54.250 | |
| Price To Operating Cash Flow Ratio | 49.609 | 27.195 | 44.431 | 35.389 | 50.676 | |
| Debt To Assets Ratio | 0.000 | 0.002 | 0.022 | 0.026 | 0.030 | |
| Debt To Equity Ratio | 0.000 | 0.002 | 0.029 | 0.030 | 0.034 | |
| Debt To Capital Ratio | 0.000 | 0.002 | 0.028 | 0.029 | 0.033 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.150 | 1.133 | 1.290 | 1.161 | 1.148 | |
| Working Capital Turnover Ratio | 1.217 | 1.159 | 1.020 | 0.771 | 0.652 | |
| Operating Cash Flow Ratio | 2.451 | 3.010 | 0.825 | 1.174 | 1.650 | |
| Operating Cash Flow Sales Ratio | 0.298 | 0.350 | 0.205 | 0.188 | 0.269 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.689 | 0.688 | 0.405 | 0.813 | 0.934 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.000 | 165.653 | 6.591 | 4.554 | 4.536 | |
| Capital Expenditure Coverage Ratio | 3.213 | 3.201 | 1.682 | 5.356 | 15.178 | |
| Dividend Paid And Capex Coverage Ratio | 1.094 | 1.182 | 0.634 | 0.696 | 15.178 | |
| Dividend Payout Ratio | 0.669 | 0.711 | 0.769 | 0.979 | 0.000 | |
| Enterprise Value Multiple | 38.595 | 25.696 | 24.465 | 17.782 | 45.450 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 76.8% | ▼-0.2% | ▼-0.1% |
| Ebit Margin | 33.8% | ▲0.7% | ▲3.0% |
| Ebitda Margin | 36.7% | ▲2.4% | ▲3.9% |
| Operating Profit Margin | 31.2% | ▲1.2% | ▲2.3% |
| Pretax Profit Margin | 33.8% | ▲0.7% | ▲3.0% |
| Continuous Operations Profit Margin | 26.8% | ▲0.6% | ▲1.7% |
| Net Profit Margin | 26.8% | ▲0.6% | ▲1.7% |
| Bottom Line Profit Margin | 26.8% | ▲0.6% | ▲1.7% |
| Current Ratio | 7.977 | ▼-0.863 | ▼-0.364 |
| Quick Ratio | 6.835 | ▼-0.782 | ▼-0.624 |
| Solvency Ratio | 1.756 | ▲0.013 | ▲0.455 |
| Cash Ratio | 5.025 | ▼-1.111 | ▼-0.989 |
| Price To Earnings Ratio | 54.961 | ▲18.776 | ▲12.043 |
| Price To Earnings Growth Ratio | 3.342 | ▲0.266 | ▲1.666 |
| Forward Price To Earnings Growth Ratio | 3.342 | ▲0.266 | ▲1.666 |
| Price To Earnings Diluted Ratio | 55.589 | ▲18.922 | ▲12.069 |
| Price To Earnings Diluted Growth Ratio | 3.335 | ▲0.035 | ▲1.623 |
| Price To Book Ratio | 13.080 | ▲5.053 | ▲4.638 |
| Price To Sales Ratio | 14.766 | ▲5.252 | ▲4.023 |
| Price To Free Cash Flow Ratio | 72.029 | ▲32.478 | ▲8.237 |
| Price To Operating Cash Flow Ratio | 49.609 | ▲22.414 | ▲8.149 |
| Debt To Assets Ratio | 0.000 | ▼-0.002 | ▼-0.016 |
| Debt To Equity Ratio | 0.000 | ▼-0.002 | ▼-0.019 |
| Debt To Capital Ratio | 0.000 | ▼-0.002 | ▼-0.018 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.150 | ▲0.017 | ▼-0.027 |
| Working Capital Turnover Ratio | 1.217 | ▲0.058 | ▲0.253 |
| Operating Cash Flow Ratio | 2.451 | ▼-0.560 | ▲0.629 |
| Operating Cash Flow Sales Ratio | 0.298 | ▼-0.052 | ▲0.035 |
| Free Cash Flow Operating Cash Flow Ratio | 0.689 | ▲0.001 | ▼-0.017 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.000 | ▼-165.653 | ▼-36.267 |
| Capital Expenditure Coverage Ratio | 3.213 | ▲0.012 | ▼-2.513 |
| Dividend Paid And Capex Coverage Ratio | 1.094 | ▼-0.088 | ▼-2.663 |
| Dividend Payout Ratio | 0.669 | ▼-0.042 | ▲0.043 |
| Enterprise Value Multiple | 38.595 | ▲12.899 | ▲8.197 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.24B | $696.9M | $598.3M | $355.4M | $570.5M | |
| Enterprise value | $1.19B | $644.8M | $550.5M | $299.6M | $511.0M | |
| EV / Sales | 14.16x | 8.80x | 8.40x | 5.62x | 12.22x | |
| EV / Op. cash flow | 47.56x | 25.16x | 40.89x | 29.84x | 45.39x | |
| EV / Free cash flow | 69.05x | 36.59x | 100.87x | 36.69x | 48.59x | |
| EV / EBITDA | 38.59x | 25.70x | 24.46x | 17.78x | 45.45x | |
| Net debt / EBITDA | -1.66x | -2.08x | -2.12x | -3.31x | -5.29x | |
| Current ratio | 7.98x | 8.84x | 4.66x | 9.06x | 11.18x | |
| Income quality | 1.11x | 1.33x | 0.78x | 0.78x | 1.21x | |
| Graham number | $17 | $15 | $13 | $12 | $10 | |
| Graham net-net | $4 | $4 | $4 | $5 | $5 | |
| Tax burden | 79.3% | 79.2% | 79.1% | 79.3% | 94.8% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $71.0M | $66.7M | $59.7M | $68.9M | $69.4M | |
| Invested capital | $98.3M | $86.8M | $73.5M | $75.6M | $75.1M | |
| Return on assets | 20.7% | 19.6% | 18.7% | 15.0% | 11.3% | |
| Operating ROA | 25.3% | 23.1% | 22.6% | 18.6% | 12.8% | |
| Return on tangible assets | 21.3% | 20.2% | 19.2% | 15.4% | 11.4% | |
| Return on equity | 23.8% | 22.2% | 24.1% | 17.4% | 12.9% | |
| Return on invested capital | 21.0% | 19.3% | 20.8% | 16.0% | 12.2% | |
| Return on capital employed | 26.5% | 24.5% | 26.4% | 20.3% | 12.9% | |
| Earnings yield | 1.8% | 2.8% | 2.9% | 3.6% | 1.6% | |
| Free cash flow yield | 1.4% | 2.5% | 0.9% | 2.3% | 1.8% | |
| Capex / Op. cash flow | 31.1% | 31.2% | 59.5% | 18.7% | 6.6% | |
| Capex / Depreciation | 666.0% | 979.0% | 1046.4% | 279.6% | 52.7% | |
| Capex / Sales | 9.3% | 10.9% | 12.2% | 3.5% | 1.8% | |
| SG&A / Sales | 42.0% | 43.1% | 41.6% | 43.9% | 48.6% | |
| R&D / Sales | 3.5% | 3.9% | 4.4% | 4.3% | 4.6% | |
| Stock comp / Sales | 3.5% | 3.4% | 3.3% | 2.6% | 3.5% | |
| Intangibles / Total assets | 3.1% | 3.2% | 2.7% | 2.4% | 1.3% | |
| Days sales outstanding | 60d | 53d | 68d | 91d | 45d | |
| Days payables outstanding | 34d | 41d | 44d | 55d | 29d | |
| Operating cycle | 277d | 277d | 372d | 254d | 206d | |
| Cash conversion cycle | 243d | 236d | 328d | 199d | 176d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+77.6%EV / Sales ▲+60.8%EV / EBITDA ▲+50.2%EV / Op. cash flow ▲+22.396Earnings yield ▼-0.009Graham number ▲+1.897
Profitability
Return on equity ▲+0.016Return on assets ▲+0.011Return on invested capital ▲+0.017Return on capital employed ▲+0.021Operating ROA ▲+0.022Income quality ▼-0.223Tax burden +0.000
Efficiency
Days sales outstanding ▲+6.909Days payables outstanding ▼-6.893Operating cycle ▼-0.236Cash conversion cycle ▲+6.656Capex / Sales ▼-0.017R&D / Sales ▼-0.003
Balance-sheet strength
Current ratio ▼-0.863Net debt / EBITDA ▲+0.411Working capital ▲+4293089.000Invested capital ▲+11468913.000Intangibles / Total assets -0.000
Change over 5 years
Valuation
Market cap ▲+116.9%EV / Sales ▲+15.8%EV / EBITDA ▼-15.1%EV / Op. cash flow ▲+2.169Earnings yield ▲+0.002Graham number ▲+7.228
Profitability
Return on equity ▲+0.108Return on assets ▲+0.094Return on invested capital ▲+0.088Return on capital employed ▲+0.136Operating ROA ▲+0.125Income quality ▼-0.098Tax burden ▼-0.155
Efficiency
Days sales outstanding ▲+14.681Days payables outstanding ▲+4.819Operating cycle ▲+71.570Cash conversion cycle ▲+66.750Capex / Sales ▲+0.075R&D / Sales ▼-0.010
Balance-sheet strength
Current ratio ▼-3.198Net debt / EBITDA ▲+3.629Working capital ▲+1600800.000Invested capital ▲+23170756.000Intangibles / Total assets ▲+0.018
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-04 iRadimed Corp (IRMD) Stock Down 3.8% but Still Overvalued -- GF Score: 92/100 On September 04, 2026, iRadimed Corp (IRMD) shares fell 3.8%, currently trading at $83.45. The stock has seen a notable decline, with a 52-week high of $107.90
- 2026-08-27 Algert Global LLC Sells 15,062 Shares of iRadimed Corporation $IRMD Algert Global LLC trimmed its stake in iRadimed Corporation (NASDAQ: IRMD) by 17.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 72,994 shares of the medical equipment provider''s stock after selling 15,062 shares during the period. Algert Global
- 2026-08-10 iRadimed Corporation (NASDAQ:IRMD) Given Consensus Recommendation of “Moderate Buy” by Brokerages Shares of iRadimed Corporation (NASDAQ: IRMD - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five ratings firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong
- 2026-07-31 iRadimed Q2 Earnings Call Highlights iRadimed NASDAQ: IRMD reported second-quarter 2026 revenue of $20.5 million, up 0.5% from a year earlier, as the company began general-release production of its new 3870 MRI IV pump system and worked through the costs associated with an initial manufacturing ramp.
- 2026-07-31 IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript
- 2026-07-31 IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $20.5 million for the second quarter of 2026, which increased by $0.1 million, or 0.5% compared to the same period in 2025. Reports GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46 for the second quarter of 2026.
- 2026-07-24 IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026 ORLANDO, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 second quarter financial results before the market opens on Friday, July 31, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.